Novo Nordisk A/S (NYSE:NVO)
$ 132.92 0.51 (0.39%) Market Cap: 592.14 Bil Enterprise Value: 594.69 Bil PE Ratio: 45.72 PB Ratio: 41.05 GF Score: 92/100

Novo Nordisk A/S to Discuss Rybelsus® US Approval Call Transcript

Sep 23, 2019 / 06:00AM GMT
Release Date Price: $26.49 (+0.06%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the investor call following the approval of Rybelsus in the U.S.A. (Operator Instructions) After the speaker presentation, there will be a question-and-answer session. (Operator Instructions) I must advise you that today's call is being recorded, Monday, the 23rd of September 2019.

And I should now hand over to your speaker for today, Karsten Munk Knudsen. Please go ahead.

Karsten Munk Knudsen;S;Executive VP;CFO
Novo Nordisk A

/-&

Thank you. Welcome to this Novo Nordisk's conference call regarding the regulatory approval of Rybelsus in the U.S. I'm Karsten Munk Knudsen, the CFO of Novo Nordisk. With me, I have our Chief Science Officer, Mads Krogsgaard Thomsen. Present are also our Investor Relations officers. Today's conference call and slides are available on our website, novonordisk.com. The conference call is scheduled to last 30 minutes. We will start with a brief presentation followed by a Q&A session beginning in about 10

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot